Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

C. Issa, Ghayas; Aldoss, Ibrahim; J. Thirman, Michael; F. DiPersio, John; Arellano, Martha; S. Blachly, James; N. Mannis, Gabriel; E. Perl, Alexander; S. Dickens, David; M. McMahon, Christine; Traer, Elie; Michel Zwaan, C.; Grove, Carolyn; M. Stone, Richard; J. Shami, Paul; Mantzaris, Ioannis; Greenwood, Matthew; Shukla, Neerav; Cuglievan, Branko; Kovacsovics, Tibor; Gu, Yu; G. Bagley, Rebecca; Madigan, Kate; Chudnovsky, Yakov; Van Nguyen, Huy; McNeer, Nicole; M. Stein, Eytan; H. Wei, Andrew; Fleming, Shaun; Sabins, Himalee; Aldoss, Ibrahim; Kovacsovics, Tibor; M. Stone, Richard; Arellano, Martha; R. Patel, Manish; Talati, Chetasi; Chen, Jing; Nachmias, Boaz; Heiblig, Maël; Fernandez, P; Arnan-Sangerman, Montserrat; M. Stein, Eytan; Mantzaris, Ioannis; S. Blachly, James; Traer, Elie; Michael Zwaan, C.; Wolach, Ofir; Marconi, Giovanni; Bajel, Ashish; Grove, Carolyn; N. Mannis, Gabriel; C. Schuh, Andre; J. Thirman, Michael; Byrd, John; M. McMahon, Christine; S. Dickens, David; E. Perl, Alexander; Greenwood, Matthew; C. Issa, Ghayas; A. Whitlock, James; J. Shami, Paul; F. DiPersio, John

doi:10.1200/jco.24.00826

Public

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Published in Journal of Clinical Oncology • Aug 9, 2024

Authors:

Ghayas C. Issa

Ibrahim Aldoss

Michael J. Thirman

Abstract

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with KMT2A -rearranged ( KMT2Ar ) acute leukemia. Here, we evaluated the activity of revumenib in ...

Subject

Augment

Medicine

Refractory (planetary science)

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!